Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan Pharmacogenomics in Small Cell Lung Cancer
NCT07145333Phase 3Active, not recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of topotecan in small cell lung cancer (SCLC). Started Oct 2026; status: active, not recruiting.
02
Drugs
topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07145333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145333.